|
USP E&L system suitability standards
|
|
1
|
64
|
October 27, 2026
|
|
Designing Oral Solid Drug Products to Minimize NDSRI Formation: Formulation Drivers, Mitigation Strategies and Lifecycle Control-Pub
|
|
0
|
163
|
October 22, 2026
|
|
NOx mediation - how to reduce levels
|
|
14
|
442
|
October 22, 2026
|
|
N-Nitrosoatorvastatin and applicable potency category 4 or 5
|
|
4
|
285
|
October 22, 2026
|
|
US FDA- Generic Drug Science and Research Priority Initiatives for Fiscal Year (FY) 2024
|
|
3
|
737
|
October 21, 2026
|
|
EMA/ CMDh meeting - Sept 2026 - BE requirements following formulation changes
|
|
0
|
155
|
October 21, 2026
|
|
N-nitroso-atorvastatin
|
|
4
|
144
|
October 21, 2026
|
|
Matrix interference for NDBA quantification -anybody?
|
|
2
|
203
|
October 20, 2026
|
|
Fiscal Year 2026 Generic Drug Science and Research Initiatives Public Workshop
|
|
8
|
631
|
October 19, 2026
|
|
Managing Analytical Procedure Lifecycles: Resolving Longstanding Mass Spectrometry Challenges
|
|
0
|
114
|
October 17, 2026
|
|
π―π΅ Product recall due N-nitroso-diisopropanolamine
|
|
1
|
238
|
October 17, 2026
|
|
Effective management of N-nitrosamines associated with leachables from packaging systems
|
|
7
|
547
|
October 16, 2026
|
|
LTL Application Monthly Administration
|
|
1
|
142
|
October 16, 2026
|
|
π―π΅ Recommendations by Japanese Society of Generic and Biosimilar Medicines
|
|
0
|
95
|
October 16, 2026
|
|
Managing nitrosamine toxicological risk in late-stage development
|
|
1
|
191
|
October 15, 2026
|
|
Nitrosation of bilastine
|
|
10
|
491
|
October 15, 2026
|
|
qNMR Summit 2027 in Tokyo - January 27-29, 2027
|
|
2
|
24
|
October 14, 2026
|
|
USP Knowledge Exchange Terms of Use
|
|
0
|
37
|
October 13, 2026
|
|
πΈπ¦ Saudi FDA requesting Nitrosamines Risk Assessments
|
|
6
|
2114
|
October 13, 2026
|
|
N-nitroso Des-ethyl Abemaciclib
|
|
0
|
97
|
October 12, 2026
|
|
Synthesis of N-Nitroso Finerenone
|
|
10
|
1179
|
October 12, 2026
|
|
Formation of N-nitroso compounds: Chemistry, kinetics, and in vivo occurrence
|
|
0
|
194
|
October 9, 2026
|
|
Amine nitrosation mechanism (organic medium)
|
|
1
|
145
|
October 9, 2026
|
|
In situ Formation and NNNT increase over time
|
|
6
|
385
|
October 7, 2026
|
|
Call to review USP Risk Assessment Review Toolbox
|
|
127
|
4457
|
October 2, 2026
|
|
Confirmatory testing - on how many batches?
|
|
6
|
416
|
October 2, 2026
|
|
Excipient nitrite levels are not static material attributes: Nitrite generation from environmental NOx and implications for drug product manufacturing
|
|
12
|
909
|
October 2, 2026
|
|
Qualitative & Quantitative Analysis of Nitrosamines by FTIR
|
|
8
|
447
|
September 28, 2026
|
|
Issue Regarding Purchase of N-Nitroso N-Desmethyl Rosuvastatin Reference Standard
|
|
12
|
582
|
September 26, 2026
|
|
Applicability of the ICH M7 Guidelines for Assessing Less-than-Lifetime Exposure to Nitrosamine Impurities in Drug Products-Pub
|
|
10
|
831
|
September 25, 2026
|